|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We included patients with malignant melanoma who underwent a single injection [<sup>18</sup>F]FDG dual-imaging protocol that included whole-body PET/CT and subsequent whole-body PET/MRI for staging or restaging purposes in a prospective setting.
|
31363965 |
2019 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Detecting BRAFV600 status in melanoma based on <sup>18</sup>F-FDG PET/CT alone does not yet provide clinically relevant knowledge.
|
31481581 |
2019 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
18F-FDG PET/CT of Multiorgan Sarcoid-Like Reaction During Anti-PD-1 Treatment for Melanoma.
|
31584495 |
2019 |
|
melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Positron emission tomography (PET)-CT in May 2017 identified an FDG avid omental deposit; consistent histologically with MM when resected.
|
30665926 |
2019 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Prediction of response to immune checkpoint inhibitor therapy using 18F-FDG PET/CT in patients with melanoma.
|
31335691 |
2019 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The current meta-analysis showed a high sensitivity and specificity of 18F-FDG-PET or PET/CT for the detection of recurrent disease after treatment of MM.
|
31437839 |
2019 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Can integrated 18F-FDG PET/MR replace sentinel lymph node resection in malignant melanoma?
|
29876618 |
2018 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Feasibility of clinical imaging of increased splenic FDG uptake was demonstrated in a melanoma patient participating in a clinical phase 1 trial of a tetravalent RNA-lipoplex cancer vaccine.
|
30112704 |
2018 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
<sup>18</sup>F-FDG PET imaging has transformed diagnostic nuclear medicine and has become an essential component in the management of melanoma, but still has its drawbacks.
|
29085965 |
2018 |
|
melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Hibernoma as an incidental finding in the 18F-FDG PET/CT of a patient with melanoma.
|
30358644 |
2018 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Subsequent F-FDG PET/CT and excision confirmed this to be an in-transit melanoma metastasis.
|
29742609 |
2018 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aim of the study was to evaluate if 18F-FDG-PET has the potential to detect complete responders to PD1-therapy in patients with unresectable metastasized melanoma two weeks after therapy initiation.
|
28831583 |
2018 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
FDG PET/CT has high sensitivity and specificity for the detection of distant metastases from cutaneous melanoma.
|
27775937 |
2017 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We present a case of melanoma in sinuses without abnormal F-FDG activity anywhere in the scanned portion of the body.
|
28872554 |
2017 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Unusual diffuse liver <sup>18</sup>F-FDG uptake in melanoma patient treated by ipilimumab.
|
28697198 |
2017 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The Advantages and Challenges of Using FDG PET/CT for Response Assessment in Melanoma in the Era of Targeted Agents and Immunotherapy.
|
28389693 |
2017 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ipilimumab-Induced Organizing Pneumonia on 18F-FDG PET/CT in a Patient With Malignant Melanoma.
|
28481788 |
2017 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
FDG PET/CT is a suitable modality for early detection of asymptomatic recurrence of malignant melanoma.
|
28154879 |
2017 |